GE Healthcare Technologies (GEHC) said Monday it completed the acquisition of the remaining 50% stake it doesn't own in Japanese radiopharmaceutical company Nihon Medi-Physics from Sumitomo Chemical.
As part of the deal, Kevin O'Neill, the chief executive of GE Healthcare's pharmaceutical diagnostics segment, will become president of Nihon Medi-Physics.
The company expects the transaction, which was disclosed in December, to be neutral to adjusted earnings per share in year one and accretive afterwards.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。